- Home
- GLUE vs SBET Comparison
GLUE vs SBET Comparison
Compare GLUE & SBET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | SBET |
|---|---|---|
| Founded | 2019 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GLUE | SBET |
|---|---|---|
| Price | $13.42 | $8.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $32.00 | $18.71 |
| AVG Volume (30 Days) | 1.5M | ★ 8.2M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,672,000.00 | $28,055,000.00 |
| Revenue This Year | N/A | $105.19 |
| Revenue Next Year | $2.45 | $13.53 |
| P/E Ratio | $72.42 | ★ N/A |
| Revenue Growth | 63.54 | ★ 666.04 |
| 52 Week Low | $4.68 | $4.46 |
| 52 Week High | $25.77 | $19.53 |
Technical Indicators
Market Signals| Indicator | GLUE | SBET |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 71.27 |
| Support Level | $13.95 | $6.05 |
| Resistance Level | $16.66 | $10.91 |
| Average True Range (ATR) | 0.64 | 0.41 |
| MACD | 0.06 | 0.20 |
| Stochastic Oscillator | 23.36 | 81.71 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About SBET SharpLink Gaming Ltd.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.